Clinical trial NCT03710577: Endocannabinoid and Psychological Responses to Yoga in Healthy Adults
Official title: Endocannabinoid and Psychological Responses to Yoga in Healthy Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
First posted: 2018-10-18
Enrollment: 12
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: The proposed study is an acute, single group, crossover pilot study where participants will complete control and experimental conditions.
Primary purpose: OTHER

Brief summary: This study evaluates the acute effect of yoga on plasma levels of endocannabinoids and mood (i.e., mood disturbance, anxiety, pain) compared to one session of quiet rest. Participants completed one session of yoga and one session of quiet rest on two separate days.


Eligibility criteria: Inclusion Criteria:

* greater than or equal to 18 years old and \< 45 years old and
* report being healthy.

Exclusion Criteria:

* Being pregnant or planning to become pregnant,
* currently smoking,
* having a history of light headedness or fainting during blood draws or physical activity,
* having a history of chest pain during physical activity,
* having a bone, joint, cardiac, or other medical condition that a doctor has said may be worsened by physical activity,
* taking medications for any chronic diseases such as high blood pressure or diabetes,
* responding 'Yes' to any of the seven questions on the Par-Q.

Primary outcomes:
measure: Change in Plasma Concentration of N-arachidonoylethanolamine
timeFrame: This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)
measure: Change in Plasma Concentration of 2-Arachidonoylglycerol (2-AG)
timeFrame: This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)
Secondary outcomes:
measure: Change in Total Mood Disturbance as Measured by the Profile of Mood States
timeFrame: This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)
measure: Change in State Anxiety as Measured by the State-Trait Anxiety Inventory
timeFrame: This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)
measure: Change in Total Pain as Measured by the Short-form McGill Pain Questionnaire
timeFrame: This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)
Other outcomes:
Locations:
city: Madison
country: United States
facility: University of Wisconsin-Madison Natatorium
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: Kelli Koltyn, PhD
role: PRINCIPAL_INVESTIGATOR
References: